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Abstract: Anti-idiotypic antibodies (anti-ids) are part of natural
immune responses with regulatory capacity. Their effect on an
antigen-specific, so-called Ab1 antibody response, is dependent on
1) the original antigen, which they mirror, being Ab2 antibodies, and
2) their isotype. In the case of IgE-mediated allergy, natural anti-ids
against allergen-specific IgE represent internal images of allergen
molecules. A key biologic feature of allergens is that they can
crosslink IgE, expressed by B-lymphocytes or passively bound via
high affinity receptors to effector cells, which renders cellular
activation. Therefore, the IgE cross linking capability of anti-ids
determines whether they dampen or enhance immediate-type hyper-
sensitivity. Correspondingly to classic antiallergen blocking IgG anti-
bodies, anti-ids may also interact with inhibitory FcRIIb receptors and,
thereby, down-regulate TH2-type inflammation. Anti-ids and other
B-cell epitope mimetics, like mimotopes and DARPins, represent an-
tigen surrogates, which can be used for vaccination. Intriguingly, they
may induce antibody responses without activating potentially proin-
flammatory, antiallergen T-lymphocytes. Taken together, collective
evidence suggests that anti-ids, although representing immunologic
classics, are a timeless concept in allergology.
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INTRODUCTION
Besides a specific antigen binding site, antibody moleculespossess antigenic determinants themselves. When these
epitopes are located within the variable region of an antibody,
they are designated idiotopes. Hence, each Fab arm of an
antibody displays a set of idiotopes, representing epitopes for
complementary antibody molecules (Fig. 1), so called anti-
idiotypic antibodies (anti-ids). Anti-ids are part of regular im-
mune responses and are thought to result in a web of interacting
idiotypes. Classically, Jerne defined the order of an antibody
response as follows: Antibody Ab1 is produced in response to
an antigen and induces the production of anti-idiotypic Ab2,
which can in turn stimulate the synthesis of an anti-(anti-
idiotypic) antibody Ab3, and so forth (Fig. 1). Anti-idiotypic
antibodies (Ab2) can be classified into several categories
according to their fine specificity (Fig. 2): 1) conventional
Ab2 antibodies recognize idiotopes of Ab1 outside of its
antigen binding site, but still within the variable region; 2)
internal image Ab2 antibodies recognize idiotopes directly
within the antigen binding site of Ab1 and, therefore, mimic its
original antigen epitope like “internal images”; 3) in case the
idiotope recognized by Ab2 is not completely overlapping but
close to the antigen binding site of Ab1, it may still be able to
interfere with the antigen binding and is called Ab2. Conse-
quently, binding of antigen by Ab1 is not affected by Ab2, may
be blocked by Ab2 and is completely blocked by Ab2.
ANTI-IDS IN EXPERIMENTAL STUDIES:
THE BEGINNING
The first experiments regarding anti-ids were animal stud-
ies, which were performed to evaluate the effect of anti-ids either
on an upcoming or ongoing immune response.
For instance, Cosenza and coworkers designed a mouse
study where they used a monoclonal IgA antibody derived from
the myeloma cell line TEPC 15, specific for the hapten phos-
phorylcholine.1 To generate an anti-idiotypic immune response,
mice were immunized with the myeloma antibody Ab1 and sera
were harvested. Parallel, they immunized another group of
BALB/c mice with heat-killed pneumococci to induce a phos-
phorylcholine-specific Ab1 response. As a proof for the induc-
tion of specific antibodies, erythrocytes attached to either pneu-
mococcal C polysaccharide or phosphorylcholine were
incubated with the splenocytes from the latter group of mice,
resulting in hemolytic plaques because of immune complex-
mediated complement activation.2 Importantly, when spleen
cells were preincubated with the anti-idiotypic serum generated
upon immunization with myeloma IgA, plaque formation was
specifically inhibited because of blockage of Ab1. This principle
was later also shown for anti-ids directed against Ab1 specific
for group A streptococcal antigen.3
However, anti-ids could not only inhibit effector re-
sponses, but also prevent de novo induction of specific
immune responses in vivo. Naive BALB/c mice were admin-
istered the anti-idiotypic serum derived from immunization
with TEPC myeloma IgA and subsequently intravenously
immunized pneumococci. Antibody responses to phosphoryl-
From the IPAP-Department of Pathophysiology and Allergy Research,
Center of Pathophysiology, Infectiology, and Immunology, Medical
University of Vienna, Vienna, Austria.
This work was supported by the SFB grant F1808-B13 and the Hertha
Firnberg stipend T283-B13, both of the Austrian Science Fund (FWF).
Correspondence to: Erika Jensen-Jarolim, MD, Department of Pathophysi-
ology and Allergy Research, Medical University of Vienna, AKH-
EB03.Q, Wäehringer Gu¨rtel 18-20, 1090 Vienna, Austria.
Telephone: 43-1-40400-5120. Fax: 43-1-40400-5130. E-mail: erika.
jensen-jarolim@meduniwien.ac.at.
Copyright © 2010 by World Allergy Organization
WAO Journal ● June 2010 195
choline but not to an irrelevant control allergen were com-
pletely blocked. Thus, anti-ids were discussed to be directed
also against membrane immunoglobulins of naive antigen-
specific B cells. Accordingly, it was hypothesized that mem-
brane and secreted immunoglobulins share similar variable
domains even when belonging to different isotypes.1,4 The
key result of these studies was, however, that anti-ids act at
the cellular level to specifically suppress antibody formation.
Hart and his group generated anti-ids by immunization of
rabbits with p-azophenylarsonate-specific mouse antibodies.
When naive mice were then injected with the anti-idiotypic
rabbit serum and afterward challenged with KLH (keyhole
limpet hemocyanin)-linked azophenylarsonate, de novo anti-
body formation was suppressed up to 97%.5 However, the
suppression was not complete. This might have been because of
the appearance of antibody responses directed against either the
carrier protein KLH or the hapten (p-azophenylarsonate) as
such. It seemed probable that the induced antiphenylarsonate
antibodies (and their anti-ids), induced by carrier-hapten immu-
nization, possessed idiotypes other than those elicited by either
KLH or the hapten. Again, the conclusion of this study was that
anti-ids acted suppressive at the cellular level via binding to
immunoglobulins expressed by B-lymphocytes.
Furthermore, it became apparent that T cell receptors
carry idiotypes similar to those of immunoglobulins, meaning
that anti-ids could potentially regulate both, B-lymphocyte
and T-lymphocyte function.6 The idiotypic relationship be-
tween hypervariable domains of T and B lymphocyte recep-
tors has indeed been repeatedly documented.7–10 Further-
more, it has been shown that anti-ids can mediate cooperation
between T and B lymphocytes (Fig. 3C). Furthermore, when
B-lymphocytes expressing membrane Ab1 (mAb1) are tar-
geted by Ab2, they internalize and process the anti-id (Fig.
3B) like the original antigen (Fig. 3A). Consequently, an
anti-idiotypic peptide of Ab2 is presented in an MHC II
context to T cells, again resulting in T cell-help. This would
be an additional explanation for how B-lymphocytes recruit T
cell help. In the early 1980s, also Blaser et al identified
idiotypes on specific T-helper cells similar to the antigen-
specific IgG. However, they dissected an antihapten from an
anticarrier response and proposed that, in contrast to the
above, especially an anticarrier anti-id might block T-helper
cell function, rendering reduced antibody production.11
Taken together, already at that timepoint, functional
similarity between antigen and anti-id could be shown. There
was mostly evidence that administration of anti-ids sup-
pressed specific idiotype production.4,12 However, other
studies13 suggested that under certain conditions anti-ids
could enhance immune responses. For instance, adminis-
tration of anti-ids of the IgG1 isotype raised in A/J mice
against an antistreptococcal antigen A antibody (Ab1)
could prime animals for a secondary boost to the antigen.
Interestingly, anti-ids of the IgG2 isotype were rather
FIGURE 1. The anti-idiotypic network amplifies antigenic
signals. (A) An antibody Ab1 is produced in response to a
specific antigen. (B) With a defined idiotype, Ab1 induces
the production of an anti-idiotypic antibody Ab2. This Ab2
may resemble the original antigen as an internal image. (C)
Ab2 can stimulate the synthesis of an anti(anti-idiotypic) anti-
body Ab3 which principally is of the same specificity as Ab1.
FIGURE 2. Categories of anti-idiotypic antibodies. Ab2
antibodies recognize idiotopes outside the antigen binding
site, but still within the variable region of Ab1. Ab2 recog-
nizes idiotopes close to the antigen binding site of Ab1 and
thus may interfere with the antigen binding. Internal image
Ab2 binds directly within the antigen binding site.
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associated with suppressive effects on naive, antigen-
sensitive B cells.12 Therefore, besides antigen-specificity
of the anti-idiotypic system, also the induced isotype
seemed to contribute to the regulatory capacity of anti-ids.
NATURAL ANTI-IDs TO ALLERGEN-SPECIFIC IGE:
QUALITATIVE AND QUANTITATIVE STUDIES
In allergy research, Malley et al reported the influence of
anti-ids on primary and secondary IgE antibody responses to
timothy grass (Phleum pratense) pollen extract.14 An anti-idio-
typic antibody was produced to the grass pollen-specific IgE and
was administered intraperitoneally followed by immunization of
mice with timothy grass pollen extract. This anti-id profoundly
prevented IgE production toward the allergen extract, and sup-
pressed even up to 75% of the IgE response to a secondary
boost. This suppression persisted for at least 35 days.14
Despite optimistic results such as these, the role of anti-
idiotypic immune responses in humans induced during long-
time immunotherapy could at that time only be postulated.
Bose and colleagues did the first quantifications of
anti-ids in rye grass-allergic patients’ sera.15 Rye I-specific
IgG anti-ids were purified from a ryegrass allergic patient
who had been previously hyposensitized. In vitro, these IgG
specifically blocked the binding of IgE and IgG to group I
allergens of rye grass in sera of 20 individual allergics. This
result pointed toward the recurrence of idiotypes and a
constricted repertoire of human antibodies specific for an
allergen. The authors discussed similar idiotopes of IgG and
IgE within their antigen binding site. However, in this study
it remained unclear whether the same anti-ids were able to
inhibit antigen binding to both, IgE and IgG.
A functional distinction between paratope-associated
idiotopes versus bystander idiotopes (ie, idiotopes located out-
side the antigen-binding site) of IgE and IgG was made by the
group of Saint-Remy.16 They observed cross-reactivity of house
dust mite-specific IgE and IgG, but only with respect to by-
stander idiotopes.17 They inhibited Ab1-Ab2 interactions with
house dust mite allergens and thereby found that the majority of
natural anti-ids in mite-allergic patients was of the Ab2 type,
thus resembling internal images of the allergen. Still, the authors
suggested the epitope-specificity of IgE and IgG to be different.
Interestingly, anti-ids specific for ragweed were also
found in nonatopic individuals although to a much lesser
extent than in allergic and immunotherapy-treated pa-
tients.18–20 The authors proposed that anti-ids detected in
nonatopics probably represent a basal level of Ab1/Ab2
responsiveness because of the presence of allergen-specific
IgG, but not IgE antibodies, in health.
Anti-id levels in untreated patients sensitive to grass
pollen allergen Lol p I and in hyposensitized patients were
compared with levels in allergic donors not sensitive to Lol p
I, and nonallergic donors by Bose et al using sepharose
purification. Via binding to radiolabeled, affinity-purified
F(ab)2 fragments of Lol p I monoclonal antibodies, the
amounts of anti-ids and the ratio to allergen-specific antibod-
ies were calculated.21 Again, anti-ids were observed to be
present not only in allergic individuals but also in nonaller-
gics, although the latter did not show any detectable IgG or
IgE (Ab1) anti-Lol p I. Anti-id levels in allergics were shown
to directly correlate with the level of pollen exposure or the
hyposensitization status. In the majority of patients treated by
immunotherapy an inverse relationship between serum levels
of anti-Lol p I IgE and IgG antibodies (Ab1) and of anti-ids
(Ab2) could be observed. An initial increase of specific
idiotype (Ab1) levels was associated with a drop of the anti-id
(Ab2) level. However, like during hyposensitization, the
anti-id level later on increased toward a plateau. An increase
of Ab2 was also reported by Castracane et al in a ragweed
allergic human patient undergoing immunotherapy. They
used an antiragweed specific F(ab)2 fragment for coating in
a solid phase assay.19,20 In line with earlier observations by
Oudin and Cazenave, it had to be considered that a proportion
of the raised anti-ids was most probably not specific to Lol p
I, but could have also encountered similar idiotypes derived
from different allergens.21,22 Hebert and colleagues measured
elevated anti-id levels in sera of hyposensitized patients by
the use of 3 different murine monoclonal anti-Lol p I anti-
bodies.23 These murine antibodies were shown to share cross-
reactive idiotypes with human anti-Lol p I IgE and IgG
antibodies and therefore suitable in this study.24
FIGURE 3. Mechanisms of anti-idiotypic antibodies on B
(B) and T cell (T) interaction. (A): B cells recognize antigen
by membrane-expressed immunoglobulins (mIg) and receive
bystander help from T-helper cells. (B) Alternatively, an an-
ti-id may bind to mIg of a B-cell. This leads to processing
and MHCII display of an anti-idiotypic peptide rendering T
cell activation and help. (C) Because of idiotypic similarities
between B and T cell receptors, an anti-idiotypic antibody
may also force cooperation between B and T cells by bind-
ing to both. (D) Inhibition of B cell proliferation is achieved
by simultaneous binding of the anti-id to its corresponding
idiotype on mIg and via its Fc domain to FcRIIb on the
B-cell.
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THE FUNCTIONAL ROLE OF ANTI-IDS
IN ALLERGY
Levels of anti-ids were generally found to be higher in
healthy individuals than in untreated atopic patients. In the
latter, levels can be elevated by immunotherapeutical treat-
ment to the levels found in healthy volunteers.20,24
Valacer and colleagues inhibited IgE binding from
allergic patients to ragweed antigen by administration of
anti-ids purified from sera of nonallergic individuals. Strik-
ingly, this effect could be achieved although no allergen-
specific IgG or IgE could be detected in the sera of the
healthy donors. The authors discussed that anti-ids in healthy
persons could regulate the IgE response by suppressor mech-
anisms.25 Indeed, a dramatic suppressive effect of anti-ids on
the IgE response was observed in experimental studies. A
single anti-id directed against an idiotope of a murine anti-
body specific for a major epitope of grass pollen allergen Lol
p IV down regulated the allergen-specific IgE response pro-
foundly, whereas levels of other isotypes, for example, IgG1
and IgG2 were less affected.26
The enthusiasm about potential beneficial effects of anti-
ids in the course of immunotherapy was dampened by the
sudden awareness that anti-ids against allergen-specific IgE
antibodies potentially could also target IgE bound to effector
cells. This could lead to either mediator release by IgE-cross-
linking (Fig. 4B) like it is the case with the original antigen (Fig.
4A), or to the inhibition of allergen-induced release (Fig. 4D). In
fact, Geha et al demonstrated that passive cutaneous adminis-
tration of an antitetanus toxin anti-id in a human patient elicited
positive immediate-type skin reactions.27 In another study, pas-
sive cutaneous anaphylaxis experiments in rats were chosen to
analyze the in vivo effects of anti-ids on mast cell bound IgE.
Anti-ids were raised in syngeneic mice by immunization with
dinitrophenol (DNP)-specific mouse monoclonal IgE. The anti-
idiotypic serum induced a passive cutaneous anaphylactic reac-
tion in skins of rats sensitized with the DNP-specific mouse IgE.
In contrast, the same anti-id did not elicit a reaction in DNP-IgE
sensitized rats when they simultaneously were passively admin-
istered grass pollen-specific IgE. Thus, a specific anti-id seemed
to be more effective in histamine release when less IgE speci-
ficities were present in the sensitized individual. From this it was
concluded that anti-idiotypic stimulation within a polyclonal
response, like in human atopy, would rather inhibit mediator
release (Fig. 4C). Furthermore, successful immunotherapy was
considered to rely on continuous anti-id targeting of the mast
cells rendering internalization and, therefore, depletion of cell
bound specific IgE.28
The capability of human anti-idiotypic IgG purified
from mite allergic patients to recognize cell bound IgE
idiotypes of other donors, and to induce mediator release of
basophils in the absence of allergen was demonstrated.29
Consequently, the possibility that degranulation in response
to anti-ids could be a general event in allergy was proposed.
However, the degranulating activity of anti-id preparations
varied from one patient to the other. Several mechanisms
were discussed: First, the precise specificity of anti-ids could
play a role, because framework idiotopes could be private
and, in contrast, paratope-associated idiotopes of antibodies
were found to be more common among different individuals.
Hence, the relative proportion of these 2 types of anti-ids
could explain the varying degranulating activity of single anti-id
preparations on basophils of different donors. Secondly, the
authors discussed the repertoire of anti-ids to be dependent on
the individually varying antiallergen IgE response, limiting their
degranulation capacity when testing basophils of other donors.
Taken together, the impact of anti-ids in the regulation of
IgE antibody responses to allergens has at that time not been
revealed to the same extent as for infectious diseases or in
malignancies.30–32 However, genetic engineering of antibodies
opened novel methodological possibilities for precise investiga-
tion of the effects of anti-ids in the effector phase of type I
allergy. As many studies previously were based on mouse
monoclonal anti-ids, it was difficult to extrapolate the findings to
the human setting. Therefore, the group around Shakib intended
to engineer murine/human chimeric anti-ids and the correspond-
ing antiallergen IgE,33 taking Der p 1 as a model allergen.
Testing these chimerized IgE-anti-idiotypic antibodies on
FcRIIb transfected cells and purified basophils, they found an
inhibition of the degranulation through the anti-ids. Interestingly,
a novel mechanism of action was proposed, involving FcRIIb-
binding by the Fc domain of the anti-idiotypic IgG, and,
FIGURE 4. Mechanisms of anti-idiotypic antibodies on ef-
fector cells. Mediator release of effector cells (E) is triggered
by cross-linkage of 2 receptor-bound IgE either via (A) rec-
ognition of the antigen or (B) the anti-id. (C) Effector cell
inhibition is achieved by binding of the anti-id to its specific
idiotype within a polyclonal response. (D) Cross-linkage of
FcRI and the inhibitory FcRIIb receptor via an anti-idiotypic
IgG antibody also inhibits degranulation.
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consequently, cellular inhibition through the associated ITIM-
motif of this receptor (Fig. 4D).34 In this context it is of interest
that also allergen-specific IgG may recognize allergen already
complexed with mIgE on B-lymphocytes or with IgE bound to
the high affinity receptor. Upon simultaneous binding to
FcRIIb, allergen-specific IgG has been shown to down regulate
not only effector cells, but also B-lymphocytes.35,36 Therefore,
we postulate here that similarly anti-ids may exploit this mech-
anism and act on the B cell level, too (Fig. 3D).
Interestingly, anti-ids may not only dampen the allergic
response after allergen immunotherapy, but may also have a
protective function in offsprings of allergic mothers. In a
mouse model, the maternally derived anti-id against allergen-
specific IgE was shown to induce IgE suppression in the
offspring which was long-lasting and dose-dependent.37 As
molecular modeling ruled out an internal image function of
the anti-ids, possibly also here the binding to FcRIIb could
contribute to the protective function.
ANTI-IDS PRIME AND ENHANCE
ALLERGEN-SPECIFIC IMMUNITY
It had been suggested that anti-ids function differently
in healthy, allergics, or hyposensitized patients. Bose pro-
posed 1986 that anti-ids in allergics might function as “net-
work antigens”, mimicking the allergen and therefore being
able to accelerate an immune response.21 In accordance, an
anti-idiotypic Ab2 antibody raised by a monoclonal anti-
Lol p 1 antibody was able to successfully prime an aller-
gen-specific antibody response, as a subsequent boost
injection with the antigen Lol p I resulted in a further
increase of specific IgE and IgG antibody levels.38 The admin-
istration of anti-ids augmented both, idiotype specific and total
antibody responses against the allergen,38 a result that had been
predicted before by studies outside the field of allergy.39–41
However, the exact mechanism for the enhancing effect of an
anti-id resembling only a single epitope, remained unclear.
One may speculate that upon the administration of Ab2 the
induced Ab3 facilitates subsequent antigen presentation,
leading to epitope spreading. Especially the IgM isotype was
considered to potentiate the immune response against low
doses of antigen via the idiotypic network. A further expla-
nation could be that immune complexes formed after antigen
immunization directly stimulate antigen-specific B cells.42
VACCINATION WITH ANTI-IDS TO CONTROL
TOTAL IGE LEVELS
The immunotherapeutical potency of anti-ids for allergic
patients was not only investigated with respect to the allergen-
specific IgE response, but also regarding total IgE levels in
allergics. It had been shown previously that natural anti-IgE
isotype antibodies exist, which, depending on the epitope spec-
ificity of the Fc domain, may down-regulate or enhance the
effector function of IgE.43 Stadler et al aimed to generate
nonanaphylactogenic IgG antibodies through active immuniza-
tion with an anti-idiotypic antibody as an antigen surrogate.
When they used a beneficial, nonanaphylactogenic anti-IgE
antibody (termed BSW17) as a template, anti-ids could be
generated from a combinatorial phage library displaying the Fab
repertoire of a grass pollen allergic patient.44 According to the
principle of molecular mimicry, these anti-ids resembled an
epitope of the constant domain of IgE and actively induced
BSW17-like anti-IgE specificities in mice.45 Therefore, as an
alternative to passive anti-IgE therapy with, for example, oma-
lizumab, vaccination with anti-idiotypic molecules for active
induction of a protective anti-IgE response was envisaged by the
authors.
VACCINATION WITH ANTI-IDS TO CONTROL
ALLERGEN-SPECIFIC IGE LEVELS
In our own study, we generated anti-idiotypic Fab anti-
body fragments for IgE, which was specifically directed against
timothy grass pollen allergen Phl p 5.46 The phage library
containing the repertoire of a grass pollen sensitized individual,
which is described above,47 was this time used for screening
with allergen-specific IgE. Several high-binding Fab clones with
mimicry potential to the allergen’s IgE epitope could be isolated.
Upon immunization with clones in mice, antiallergen IgG could
be induced via molecular mimicry. Furthermore, these anti-
idiotypic Fabs resembled naturally occurring IgE epitopes of the
allergen as observed by sequence analysis and molecular mod-
eling.46 More recently, we applied one of the selected anti-
idiotypic clones in a memory mouse model of acute allergic
asthma to test whether it would be suitable for immunotherapy.
According to a protocol by Mojtabavi et al48 acute allergic
asthma was induced by injecting recombinant Phl p 5 intraperi-
toneally, followed by aerosol challenges with this allergen.
Subsequently, groups of mice with acute asthma were vacci-
nated with 1) the anti-idiotypic Fab fragment, or 2) control
antigen KLH before reinduction of acute asthma by an
additional allergen aerosol challenge.
Whereas the IgE and IgG1 antibody levels of all groups
remained unchanged during treatments, the extent of acute
eosinophilic inflammation upon rechallenge with aerosolized
allergen was much lower in the Fab-treated group compared
with the untreated asthmatic and the nonasthmatic groups (data
not shown). As the specific IgE levels were not affected, it is
tempting to speculate that the reason for this profound anti-
inflammatory property might be (similarly as with peptide mi-
motopes; see below) the absence of allergen-specific T cell
epitopes in the anti-ids.49 Surface plasmon resonance studies
indicated that high affinity polyclonal IgE may exhibit a binding
behavior similar to monoclonal antibodies, indicating that each
Phl p 5 allergen might only harbor a low number of IgE
epitopes.50 Consequently, the anti-idiotypic strategy is expected
to down-regulate IgE specificities being relevant and occurring
frequently in the grass pollen allergic population.
DISTINCT TYPES OF ANTI-ID LIKE MOLECULES
Although antibodies are widely used for therapeutic ap-
plications, they have some potential drawbacks in large scale
production including low expression yields and aggregation
tendency. In this context, phage display technology does not
only enable the selection of anti-ids, but also of peptide mole-
cules, which structurally mimic B cell epitopes and therefore are
called mimotopes.51 Several allergen mimotopes were already
defined by other working groups and ourselves, like for the
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panallergen profilin,52 the major fish allergen parvalbumin,53
birch pollen allergens,54 grass pollen allergens,46,55 or house dust
mite allergens.56 Mimotopes lack allergen-specific T-cell
epitopes and have been demonstrated to induce blocking IgG
antibodies without stimulation of allergen-specific T-helper
cells.49,54 Furthermore, when therapeutically applied in a murine
model of allergic asthma, they could, like reported here for an
anti-idiotypic Fab fragment, prevent acute lung hypersensitivity
and inflammation upon allergen rechallenge.57
Still, to achieve good quality of the immune response
towards the relatively short peptide mimotopes, bystander
T-cell help was needed. The immunogenic carrier for the
mimotopes was in that case KLH providing bystander T-
helper cell epitopes. Alternatively, tetanus toxoid (TT) could
also be chosen as an immunostimulatory agent because of its
promiscuous T-cell epitopes.58
Another possibility to enhance antigenic density is the
attachment of linear peptides to tyrosine backbones. The so
called multiple antigenic peptides (MAPs) can be synthesized in
a straightforward manner and allow a dense display, most often
as tetra- or octameric constructs.59 Taken up by antigen present-
ing cells (APC), they are processed to T-cell epitopes and can
activate T-cells too. However, controversial studies have raised
the question whether or not the addition of a promiscuous
T-helper epitope to a MAP is needed for achieving a sufficient
immune response upon MAP-vaccination.60
Another option to overcome the limitations of antibody
libraries are designed ankyrin repeat proteins (DARPins).
These DARPin libraries are a source of -hairpin structures,
which mimic naturally occurring repeat proteins, and play an
important role in innate immunity61; reviewed in.62 In a study
by Vogel et al, DARPin libraries were used to isolate ligands
against the variable region of the nonanaphylactogenic anti-
IgE antibody BSW17. Confirming the high specificity of the
identified anti-idiotypic DARPins, they successfully pre-
vented binding of BSW17 to IgE-sensitized rat basophils
expressing human FcRI.63 Recent molecular studies indi-
cated that hairpin scaffold libraries render mimetics, which
closely mimic the crystal structure of a native protein.64 We
are convinced that these novel developments will open up
new avenues for anti-idiotypic strategies in allergy research.
SYNOPSIS
From several studies in the past it has emerged that natural
anti-ids take part in the regulation of the immune response
including immediate-type hypersensitivity. Obviously, each an-
tibody response to an allergen is accompanied by the production
of anti-idiotypic antibodies and anti-antibodies, together com-
posing an idiotypic regulatory network. As predicted by Jerne,
several studies could indeed show on the molecular level that
anti-ids function as internal images of allergens. Thus, it may be
hypothesized that anti-ids for allergen-specific IgE potentially
nourish IgE memory in periods of allergen absence, like for
instance outside the pollen season. In experimental studies,
anti-ids have been able to specifically down-regulate, or vice
versa, boost allergen-specific immune responses. This can on the
one hand be because of the fact that they act on B- and
T-lymphocyte antigen receptors in either a nonproductive
(monovalent) manner or in a productive way by cross linking B
cell receptors, or crosslinking B with T-lymphocytes, thereby
forcing cellular crosstalk. Furthermore, anti-ids have been found
in nonallergic individuals, pointing toward a protective regula-
tory mechanism.
Despite controversial in vitro results of the influence
of anti-ids on the allergic response, levels of anti-ids
usually get elevated during the course of specific immu-
notherapy (SIT). Therefore, anti-ids that mimic the rele-
vant structural epitopes of an allergen are possibly attractive
candidates for immunotherapy. For vaccination, mimotopes or
DARPins represent novel anti-idiotypic alternatives. We pro-
pose that with anti-idiotypic tools, being synthetic or generated
from the patient’s antibody repertoire, immunologic disorders
like allergies could be manipulated.
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